| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-02-23 | Summit Therapeutics (UK) | nomination |
Infectious diseases - Neuromuscular diseases - Rare diseases | Nomination | ||
| 2015-02-23 | Alkermes (Ireland) | nomination |
CNS diseases - Neurodegenerative diseases | Nomination | ||
| 2015-02-23 | BMS (USA - NY) Rigel Pharmaceuticals (USA - CA) | small molecule TGF beta receptor kinase inhibitors | R&D development commercialisation |
Cancer - Oncology | Development agreement | |
| 2015-02-23 | Foundation Medicine (USA -MA) H3 Biomedicine (USA -MA) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2015-02-23 | Merck&Co (USA - NJ) NGM Biopharmaceuticals (USA - CA) | multiple drug candidates currently in preclinical development at NGM, including NP201 | diabetes, obesity, nonalcoholic steatohepatitis (NASH) | R&D development commercialisation |
Metabolic diseases - Liver diseases | R&D agreement |
| 2015-02-20 | Roche (Switzerland) Sysmex Inostics (USA-Germany) | emPCR portfolio of patents, liquid biopsy RAS biomarker testing center | licensing - opening of new premises | Cancer - Oncology - Technology - Services | Opening of new premises | |
| 2015-02-19 | BiogenIdec (USA - MA) Fondazione Telethon (Italy) Ospedale San Raffaele (Italy) | gene therapies for the treatment of both hemophilia A and B | hemophilia A, hemophilia B | collaboration |
Hematological diseases - Genetic diseases - Rare diseases | Collaboration agreement |
| 2015-02-19 | Sanofi (France) | nomination |
Nomination | |||
| 2015-02-19 | Genmab (Denmark) Bionovion (The Netherlands) | bispecific antibodies targeting immune checkpoints | development commercialisation |
Cancer - Oncology | Development agreement | |
| 2015-02-19 | Nanobiotix (France) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-02-19 | Catalyst Pharmaceutical Partners (USA - FL) | nomination |
Rare diseases | Nomination | ||
| 2015-02-18 | Sanofi (France) Lead Pharma (The Netherlands) | small-molecule therapies directed against the nuclear hormone receptors called ROR gamma t | rheumatoid arthritis, psoriasis, inflammatory bowel disease | R&D development commercialisation |
Autoimmune diseases | R&D agreement |
| 2015-02-18 | Argen-X (Belgium) Lonza (Switzerland) | GS Xceed™ System | licensing production manufacturing |
Technology - Services | Licensing agreement | |
| 2015-02-18 | Pharming (The Netherlands) | nomination |
Rare diseases | Nomination | ||
| 2015-02-17 | Celladon (USA - CA) Novasep (France) | Mydicar® | advanced heart failure | production manufacturing |
Cardiovascular diseases | Production agreement |
| 2015-02-17 | Teva Pharmaceutical Industries (Israel) Eagle Pharmaceuticals (USA - NJ) | EP-3102 (bendamustine hydrochloride) | chronic lymphocytic leukemia, indolent B-cell non-Hodgkin lymphoma | licensing |
Cancer - Oncology | Licensing agreement |
| 2015-02-17 | Horizon Pharma (Ireland) | Chicago office | opening of new premises | Opening of new premises | ||
| 2015-02-17 | Asceneuron (Switzerland) | nomination |
Neurodegenerative diseases | Nomination | ||
| 2015-02-13 | Saniona (Denmark) Janssen R&D, a J&J company (USA - NJ) | medicines to treat neurological disorders | neurological disorders | development |
Neurological diseases - CNS diseases | Termination of an agreement |
| 2015-02-13 | Medtronic (USA - MN) The American Heart Association - American Stroke Association (USA) | stroke | collaboration |
Cardiovascular diseases | Collaboration agreement |
